In the last few years, multimillion dollar revenues driven by popular demand, and even higher projections for the future have catapulted obesity drugs into the mainstream. In this month’s cover story, we take a look at what’s next in this field that is currently dominated by GLP-1 receptor agonists.
Also in this issue, an interview with a leading academic highlights why regulatory bodies need to evolve with our growing understanding of the obesity and diabetes drug development field, to ensure these drugs are accessible to all who can benefit from them.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn the broader pharmaceutical space, the high-profile acquisition of Catalent has been met with some backlash, which we investigate through a comment piece. Don’t miss other stories on how pharma is preparing for climate disasters, and the latest advances in addressing the opioid crisis.
All this and the latest news and analysis on the pharmaceutical and biotech industry.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.
You can also subscribe here to receive email notifications when a new issue is available.
